Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
semaglutide 20 ml Retatrutide Shows 28.3% Weight Peptide Synthesis Tamaño:5mg
Retatrutide Shows 28.3% Weight Loss in Phase 3 Obesity Trial
(2021), Lancet 397(10286), PubMed 33894838 Statistics from preclinical literature Cagrilintide (development code AM833 ), a long-acting amylin analogue , 32 amino acids, molecular weight 3.795 kDa Developed at Novo Nordisk (Denmark) as part of the CagriSema combination program (cagrilintide + semaglutide) Target: amylin receptors (AMY1, AMY2, AMY3) + secondarily the calcitonin receptor , extended half-life via a C16 fatty acid linker Standard dose in clinical trials: 0.16–4.5 mg/week subcutaneously (Phase 1b/2) Phase 2 (Enebo 2021, n=96): 17.1 % reduction in body weight with CagriSema 2.4 mg + 2.4 mg over 20 weeks vs 9.8 % with semaglutide alone REDEFINE 1 Phase 3 (2024, preliminary data): 22.7 % weight reduction with CagriSema 2.4 mg/2.4 mg over 68 weeks Status: Phase 3 completed 2024–2025 , FDA filing expected 2025–2026 Approximately 25+ peer-reviewed publications in PubMed (2018–2024) Reference sources (PubMed) Enebo LB
Peptide Synthesis
Tamaño:5mg
The Core BMI Criteria For adults, both Wegovy and Zepbound labels include the same framework: BMI ≥ 30 kg/m² (obesity), or BMI ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity BMI is calculated as weight in kilograms divided by height in meters squared
US$ 28.59
US$ 22.08
US$ 22.53
US$ 24.51
US$ 26.40
